SCHEMBL2177387

SCHEMBL2177387

CNC(=O)c1cc2nccc(Oc3ccc(CC(=O)O)c(OC)c3)c2cc1OC

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.59
MET P08581 3/20 0.59
AURKB Q96GD4 2/20 0.59
AURKA O14965 1/20 0.59
LCK P06239 1/20 0.59
TEK Q02763 1/20 0.59
PDGFRB P09619 16/20 0.56
CSF1R P07333 13/20 0.56
AXL P30530 2/20 0.56
FLT3 P36888 4/20 0.54
PDGFRA P16234 2/20 0.51
FGFR1 P11362 2/20 0.51
FLT1 P17948 2/20 0.51
FGFR2 P21802 2/20 0.51
FLT4 P35916 2/20 0.51
PDXK O00764 1/20 0.51
RIPK2 O43353 1/20 0.51
LYN P07948 1/20 0.51
RET P07949 1/20 0.51
FGFR3 P22607 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2173716 0.96 KDR (0.59) KDRMETAURKBAURKALCK
SCHEMBL2175269 0.88 KDR (0.54) KDRMETAURKBAURKALCK
SCHEMBL2176217 0.88 PDGFRB (0.67) KDRMETAURKBAURKALCK
SCHEMBL4509974 0.85 MET (0.53) KDRMETAURKBAURKALCK
SCHEMBL2173553 0.84 AXL (0.63) KDRMETAURKBAURKALCK
SCHEMBL2174409 0.84 KDR (0.64) KDRMETAURKBAURKALCK
SCHEMBL2173684 0.82 PDGFRB (0.66) KDRMETAURKBAURKATEK
SCHEMBL2173090 0.82 PDGFRB (0.65) KDRMETPDGFRBCSF1RFLT3
SCHEMBL2172313 0.82 PDGFRB (0.57) KDRMETAURKBAURKALCK
SCHEMBL4200371 0.81 AXL (0.55) KDRMETAURKBAURKALCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973164-B2 Quinoline derivatives ASTRAZENECA AB (SE) 2011-07-05 US disclosed
US-20090076074-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2009-03-19 US disclosed
EP-1994025-A1 QUINOLINE DERIVATIVES AstraZeneca AB (SE) 2008-11-26 EP disclosed
WO-2007099326-A1 QUINOLINE DERIVATIVES ASTRAZENECA AB (SE) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076074-A1 QUINOLINE DERIVATIVES RECQL, NQO2, CCNA1 KDR 2277/4885MET 3334/4885AURKB 1165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.